Nabriva Therapeutics Plc 4

4 · Nabriva Therapeutics Plc · Filed Jun 27, 2017

Form 4

Period: 2017-06-23

Director

Transactions

Other
Stock Option
2017-06-23+40,000→ 40,000 total
Exp: 2025-07-05→ Ordinary Shares (40,000 underlying)
Other
Stock Option
2017-06-23+10,100→ 10,100 total
Exp: 2026-08-25→ Ordinary Shares (10,100 underlying)
Other
Ordinary Shares
2017-06-23+31,790→ 31,790 total

Footnotes (5)

[F1]Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
[F2]This option was granted on July 6, 2015. Vesting began on July 31, 2015 and ends on July 31, 2019. Twenty-five percent (25%) of the option vested on July 31, 2016, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
[F3]The exercise price is 6.618 Euro.
[F4]This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
[F5]The exercise price is 6.634 Euro.

Documents

1 file